$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA…
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in…
JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…
Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434…
Strategic Cost Management Signals Stronger Financial Health and Future StabilityGross profit before fair value changes reached $2.4 million, reflecting a…
BOSTON and ROLLE, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in…
Renowned Former Judge Joins Firm's Leadership Team After Two Years of Work as a Senior Attorney ATLANTA, GA / ACCESSWIRE…
Significant pipeline advancementsStrategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10BnKey senior management hires LONDON, UK /…
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASESSTRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING…
LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma Plc (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company…